Who We Are
Since GI Dynamics’ founding in 2003, our mission has been to alleviate the symptoms of type 2 diabetes and obesity for patients fighting these global epidemics worldwide.
Our revolutionary EndoBarrier® is a testament to the GI Dynamics mission. The first endoscopically delivered device therapy for the treatment of type 2 diabetes and obesity. EndoBarrier is aimed to bridge the gap between pharmaceuticals and surgery by providing an alternate treatment option to help reduce HbA1c and weight for individuals who are underserved by drugs and injections, but for whom surgery is not an option.
GI Dynamics is headquartered in Boston, Massachusetts, with offices in Europe and Australia. Our team of business experts and industry veterans have a successful track record of pioneering and commercializing breakthrough healthcare technologies.